| Antigen: |
CD19 |
| Relevance: |
CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase. |
| Clone: |
BU12 |
| Subclass: |
IgG1 |
| Applications: |
FACS, Immunohistochemistry (frozen sections), Immunoprecipitation, Functional application: induces adhesion of B cells. |
| Immunogen: |
Human EB-4 Burkitt lymphoma cell line |
| Reactivity: |
Human (reactivity with other species has not been confirmed) |
| Species raised in: |
Mouse |
| Fusion partner: |
Non secreting plasmacytoma 653/BALB/c mouse spleen cell; date of fusion; April 1984 |
| Recommended growth conditions: |
RPMI 1640 + 10% FCS |
| References: |
Behr, S. and Schriever, F. 1995 J.Exp.Med. 182(5):1191-9 
Callard, R.E. et al. 1992 J.Immunol. 148(10): 2983-7
Schlossman, S.F. et al. 1995 Leucocyte Typing V Oxford University Press |
| Notes: |
|
For further information about antibodies from CRT or to discuss sales or licensing options, please contact Reagents@cancertechnology.com
Click here to view Notes and Disclaimer information |
